Table 2.
Medication Use During Current Major Depressive Episode and Patient's Lifetime (n=18)
| No. (%) by Medication Use |
||
|---|---|---|
| Medication/Somatic Treatment | Current Major Depressive Episode | Lifetime |
| Lithium | 7 (39) | 16 (89) |
| Antidepressants | ||
| Duloxetine | 7 (39) | 13 (72) |
| SSRI | 6 (33) | 18 (100) |
| Bupropion | 5 (28) | 16 (89) |
| Venlafaxine | 2 (11) | 11 (61) |
| Trazodone | 2 (11) | 7 (39) |
| MAOI | 1 (6) | 7 (39) |
| TCA | 0 | 7 (39) |
| Mirtazapine | 0 | 6 (33) |
| Nefazodone | 0 | 3 (17) |
| Antipsychotics | ||
| Quetiapine | 9 (50) | 16 (89) |
| Aripiprazole | 2 (11) | 10 (56) |
| Risperidone | 2 (11) | 8 (44) |
| Ziprasidone | 2 (11) | 7 (39) |
| Olanzapine | 1 (6) | 7 (39) |
| Clozapine | 0 | 2 (11) |
| Conventional antipsychotics | 0 | 5 (28) |
| Anticonvulsants | ||
| Valproate | 6 (33) | 14 (78) |
| Oxcarbazepine | 4 (22) | 5 (28) |
| Lamotrigine | 3 (17) | 13 (72) |
| Carbamazepine | 1 (6) | 9 (50) |
| Topiramate | 1 (6) | 4 (22) |
| Zonisamide | 1 (6) | 1 (6) |
| Gabapentin | 0 | 3 (17) |
| Levetiracetam | 0 | 1 (6) |
| Somatic treatments | ||
| ECT | 2 (11) | 10 (56) |
| VNS | 1 (6) | 1 (6) |
| Other | ||
| Pramipexole | 0 | 2 (11) |
| Thyroid augmentation | 3 (17) | 8 (44) |
| Stimulant | 1 (6) | 8 (44) |
| Modafinil | 0 | 1 (6) |
Abbreviations: ECT, electroconvulsive therapy; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; VNS, vagal nerve stimulation.